[
    [
        {
            "time": "2022-11-01",
            "original_text": "近期多家药企公布新冠药物进展，部分上市公司或趁机“蹭热点”。",
            "features": {
                "keywords": [
                    "新冠药物",
                    "药企",
                    "蹭热点"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "近期多家药企公布新冠药物进展，部分上市公司或趁机“蹭热点”。",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-11-01",
            "original_text": "又有千亿医药巨头放大招！赴港二次上市。",
            "features": {
                "keywords": [
                    "医药巨头",
                    "赴港",
                    "二次上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "又有千亿医药巨头放大招！赴港二次上市。",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-11-01",
            "original_text": "华兰股份：公司和凯莱英有合作关系。",
            "features": {
                "keywords": [
                    "华兰股份",
                    "凯莱英",
                    "合作关系"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰股份：公司和凯莱英有合作关系。",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-11-01",
            "original_text": "21股今日获机构买入评级。",
            "features": {
                "keywords": [
                    "机构买入评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "21股今日获机构买入评级。",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-11-01",
            "original_text": "天风证券：维持凯莱英(002821.SZ)“买入”评级 签署重大合同 产能稳定释放。",
            "features": {
                "keywords": [
                    "天风证券",
                    "凯莱英",
                    "买入评级",
                    "重大合同",
                    "产能释放"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天风证券：维持凯莱英(002821.SZ)“买入”评级 签署重大合同 产能稳定释放。",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-11-01",
            "original_text": "华泰证券：维持凯莱英(002821.SZ)“买入”评级 目标价533.93元。",
            "features": {
                "keywords": [
                    "华泰证券",
                    "凯莱英",
                    "买入评级",
                    "目标价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华泰证券：维持凯莱英(002821.SZ)“买入”评级 目标价533.93元。",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-11-01",
            "original_text": "凯莱英通过港交所聆讯，多家大型银行持股。",
            "features": {
                "keywords": [
                    "凯莱英",
                    "港交所聆讯",
                    "大型银行持股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英通过港交所聆讯，多家大型银行持股。",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-11-01",
            "original_text": "医药生物行业深度报告：创新药行业景气 医药新零售东风已起。",
            "features": {
                "keywords": [
                    "医药生物",
                    "创新药",
                    "行业景气",
                    "医药新零售"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业深度报告：创新药行业景气 医药新零售东风已起。",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-11-01",
            "original_text": "港股IPO|凯莱英通过港交所聆讯 A股上市五年后再赴港股。",
            "features": {
                "keywords": [
                    "港股IPO",
                    "凯莱英",
                    "港交所聆讯",
                    "A股上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股IPO|凯莱英通过港交所聆讯 A股上市五年后再赴港股。",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-11-01",
            "original_text": "新冠特效药热度蔓延至A股：拓新药业暴涨185%后被问询停牌、翰宇药业股价翻倍后又暴跌，拼业绩还是炒概念？",
            "features": {
                "keywords": [
                    "新冠特效药",
                    "拓新药业",
                    "翰宇药业",
                    "暴涨",
                    "暴跌",
                    "炒概念"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "新冠特效药热度蔓延至A股：拓新药业暴涨185%后被问询停牌、翰宇药业股价翻倍后又暴跌，拼业绩还是炒概念？",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]